NumFin

Heron Therapeutics, Inc.

Sümbol: HRTX

NASDAQ

2.45

USD

Turuhind täna

  • -3.3392

    P/E suhe

  • 0.0254

    PEG suhe

  • 368.31M

    MRK Cap

  • 0.00%

    DIV tootlus

Heron Therapeutics, Inc. (HRTX) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Heron Therapeutics, Inc. (HRTX) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 22.897 M, mis on 0.785 % gowth. Kogu perioodi keskmine brutokasum on 13.082 M, mis on 0.677 %. Keskmine brutokasumi suhtarv on 0.632 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.178 %, mis on võrdne -0.089 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Heron Therapeutics, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.113. Käibevara valdkonnas on HRTX aruandlusvaluutas 188.774. Märkimisväärne osa neist varadest, täpsemalt 80.409, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.052%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 173.753 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.141%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud -33.973 aruandlusvaluutas. Selle aspekti aastane muutus on -3.503%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 60.137, varude hind on 42.11 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 0. Kontovõlad ja lühiajalised võlad on vastavalt 3.24 ja 3.08. Koguvõlg on 179.63, netovõlg on 150.95. Muud lühiajalised kohustused moodustavad 73.37, mis lisandub kohustuste kogusummale 256.48. Lõpuks hinnatakse viidatud aktsia 0, kui see on olemas.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990198919881987

balance-sheet.row.cash-and-short-term-investments

251.0980.484.9157.6
208.5
391
332.4
172.4
51.1
131.2
72.7
72.3
53.5
18
2.1
7.6
10.5
35.1
15.5
5.8
13.6
9.5
14.1
19.5
22.5
3.7
4.1
8.7
5.4
5.2
2.7
1.8
2.7
1.6
1.7
2.6
11.4
15.9

balance-sheet.row.short-term-investments

14751.769.567
103.4
319.1
300.5
27.8
37.7
56
0
0
0
0
0
0
0.6
1.6
13.2
5
10.5
9.4
10.8
15.9
16
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

252.0760.15235.5
41.9
39.9
64.7
41.9
2
0
0
0
0
0
0.1
0.2
0
0.2
0.1
1.5
1.5
1.3
1.5
1.5
1.7
5.1
4.8
3.4
1.7
2.5
1.9
2.8
1.6
1.2
1
0.7
0.7
0.6

balance-sheet.row.inventory

180.842.154.648.4
41.9
25
39
10.1
5.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0.1
0.1
4.6
3
2.6
2.1
7.9
7
8.4
1.4
0.5
0.3
0.1
0.1
0

balance-sheet.row.other-current-assets

42.236.11413
21.9
23.2
11.2
3.7
3.7
3.6
1.1
0.6
0.6
0.3
0.3
0.5
0.2
0.6
0.6
0.3
0.4
0.4
0.3
0.6
0.8
0.4
0.9
0.5
2.5
0.9
4.8
2.1
13.4
1.4
3.2
5.4
0.1
0

balance-sheet.row.total-current-assets

726.19188.8205.4254.4
314.2
479.1
447.2
228.1
62.1
134.8
73.7
72.9
54.1
18.2
2.5
8.3
10.8
35.8
16.2
7.6
15.5
11.3
16
21.6
25
13.8
12.8
15.2
11.7
16.5
16.4
15.1
19.1
4.7
6.2
8.8
12.3
16.5

balance-sheet.row.property-plant-equipment-net

108.425.629.833.6
39
33.4
14.7
6
5.1
3
2.8
2.9
1.8
1.1
0.4
0.5
0.9
1.1
1
1.2
1.2
1.4
1.6
1.7
1.8
8
8.6
6.8
4.7
5
5.1
5.4
4.9
3.2
3.8
4.3
4.3
4.2

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1.3
1.4
1.5
0.1
0.2
0.3
0.5
0.7
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1.3
1.4
1.5
0.1
0.2
0.3
0.5
0.7
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

39.218.115.717.7
0.3
0.3
0.3
0.3
0.3
0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.2
0.3
0.5
0.2
0.2
0.2
0.4
0.3
0.7
1.9
1.4
1.7
3.4
3.6
1.7
1.6
0.1
0.2
0.3

balance-sheet.row.total-non-current-assets

147.6233.745.551.3
39.4
33.7
14.9
6.2
5.3
3.1
3
3
1.9
1.2
0.4
0.6
1
1.2
1
1.3
1.5
1.9
1.8
1.9
1.9
9.7
10.3
9
6.7
6.6
7.1
9.3
9.2
4.9
5.4
4.4
4.5
4.5

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

873.81222.5251305.7
353.6
512.8
462.2
234.3
67.5
137.8
76.7
75.9
56
19.4
2.9
9
11.8
37
17.3
9
17
13.2
17.8
23.5
27
23.5
23.1
24.2
18.4
23.1
23.5
24.4
28.3
9.6
11.6
13.2
16.8
21

balance-sheet.row.account-payables

11.123.23.23.8
0.5
2.8
17.1
18.9
7.9
3.3
3.4
1.3
1.9
1
0.2
0.2
0.3
1.4
0.8
0.6
0.7
0.5
0.3
0.3
0.3
1
1.3
1.6
2.3
7.5
6.2
7.3
0.6
0.4
0.4
0.3
0
0

balance-sheet.row.short-term-debt

11.423.12.72.4
10.1
7.5
4.6
28.7
2.9
2.2
1.6
1
0.5
0.1
0
0
-1
-1
-1
0
0
0
0
1.4
0
0.9
3.1
2.5
0.8
0.9
2.2
0.3
0.3
0
0
0
0
0.1

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

658.46173.8154.8157.1
14.6
12.2
0
0
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2.4
0
3.1
5.6
6.4
1
3.4
3.7
4
3
3
3
3.1

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
0
0.3
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

301.5173.476.464.8
91.9
86.4
70.4
52.8
26.9
14.2
8.6
4.7
1.8
0.4
1.2
1.6
2.8
4.8
3.4
2.2
2.2
1.2
1.5
1.5
4.6
2.5
3.1
6.8
4.8
3.1
2.3
2.9
3.5
2
1.9
0.4
0.6
0.6

balance-sheet.row.total-non-current-liabilities

662.23176.8155157.1
14.6
12.2
0
0
50
0
0
0
0
0
0
0.3
1
1.3
1
0
0
0
0.3
0.8
0.9
7.1
1.1
3.1
5.5
6.4
1
3.4
3.7
4
3
3
2.9
3.1

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

23.672.88.210.4
17.6
14.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

986.28256.5237.4228.1
117.1
108.9
92
103.2
88.7
19.7
13.6
7
4.2
3.7
1.6
2.2
4.2
7.5
5.2
2.8
2.9
1.9
2.3
4.3
5.8
11.5
8.6
14
13.4
17.9
11.7
13.9
8.1
6.4
5.3
3.7
3.5
3.8

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

5.311.51.21
0.9
0.9
0.8
0.6
0.4
0.4
0.3
0.2
3
2
0.4
0.4
0.3
0.3
0.3
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-7499.81-1906-1795.5-1613.4
-1392.7
-1165.5
-960.7
-783.5
-586
-412.8
-315.2
-238.9
-183.6
-160.2
-148.4
-141.1
-131.1
-107.9
-87.8
-93
-84.8
-75.6
-71.2
-67.5
-64.9
-73.5
-70.4
-72.3
-71.6
-62.2
-52.8
-43
-33
-27.4
-23.1
-19.2
-14.7
-9.7

balance-sheet.row.accumulated-other-comprehensive-income-loss

0.01000
0.3
0.1
-0.1
0
0
0
-4.8
-4.3
-4.4
-4.3
-4.2
0
0
0
0
0
0
0
0.1
0.2
0
-0.2
-9.3
-9.5
-8.8
-7.9
-7
-6
-5.1
-4.4
-3.7
-2.9
-2.3
-1.2

balance-sheet.row.other-total-stockholders-equity

7382.021870.51807.91690
1628.1
1568.3
1330.2
914
564.3
530.6
382.8
311.9
236.8
178.3
153.5
147.5
138.4
137.1
99.6
99
98.7
86.6
86.4
89.4
88.7
95.4
94.2
92
85.4
75.3
71.6
59.5
58.3
34.9
33.1
31.6
30.3
28.1

balance-sheet.row.total-stockholders-equity

-112.47-3413.677.6
236.5
403.8
370.2
131.1
-21.3
118.1
63.1
68.9
51.8
15.8
1.3
6.8
7.6
29.5
12.1
6.2
14.2
11.3
15.5
19.2
21.2
12
14.5
10.2
5
5.2
11.8
10.5
20.2
3.1
6.3
9.5
13.3
17.2

balance-sheet.row.total-liabilities-and-stockholders-equity

873.81222.5251305.7
353.6
512.8
462.2
234.3
67.5
137.8
76.7
75.9
56
19.4
2.9
9
11.8
37
17.3
9
17
13.2
17.8
23.5
27
23.5
23.1
24.2
18.4
23.1
23.5
24.4
28.3
9.6
11.6
13.2
16.8
21

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0

balance-sheet.row.total-equity

-112.47-3413.677.6
236.5
403.8
370.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

873.81---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

14751.769.567
103.4
319.1
300.5
27.8
37.7
56
0
0
0
0
0
0
0.6
1.6
13.2
5
10.5
9.4
10.8
15.9
16
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

672.68179.6157.5159.5
24.6
19.8
4.6
28.7
52.9
2.2
1.6
1
0.5
0.1
0
0
0
0
0
0
0
0
0
0
0
3.3
3.1
5.6
6.4
7.3
3.2
3.7
4
4
3
3
3
3.2

balance-sheet.row.net-debt

568.59151142.169
-80.5
-52.1
-27.3
-115.9
39.5
-73
-71.1
-71.3
-53
-17.9
-2.1
-7.6
-10
-33.5
-2.3
-0.8
-3.1
-0.1
-3.3
-3.6
-6.5
-0.4
-1
-3.1
1
2.1
0.5
1.9
1.3
2.4
1.3
0.4
-8.4
-12.7

Rahavoogude aruanne

Heron Therapeutics, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.594 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 29.76, mis tähistab 26.196 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 0.01 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 17995000.000. See on -6.414 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 2.9, 0, -24.35, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 48.7, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989

cash-flows.row.net-income

-110.56-110.6-182-220.7
-227.3
-204.7
-178.8
-197.5
-173.1
-97.6
-76.4
-55.3
-24.4
0.4
-7.2
-10.1
-22.9
-20.2
5.3
-8.2
-9.2
-4.4
-3.8
-2.5
8.6
2.4
1.9
-0.7
-9.4
-9.4
-9.8
-9.9
-5.6
-4.3
-3.9
-4.5

cash-flows.row.depreciation-and-amortization

2.92.92.93
2.8
2
1.5
1.5
1.1
0.7
0.6
0.3
0.2
0.2
0.2
0.4
0.4
0.3
-0.2
0.4
0.3
0.5
0.5
0.4
-0.1
0.5
1.4
1.2
1.4
1.2
1.1
1.2
1.1
0.8
0.8
0.7

cash-flows.row.deferred-income-tax

-1.19-4.401.6
1
-3.6
-3.3
-0.2
0.3
0
0.9
0
0
0.1
-0.1
0
-0.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

32.8532.94346.9
50.2
51.4
33.4
30.5
26
14.4
8.1
10.9
5.7
1.9
1.7
1.1
1.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

16.7916.8-10.5-35.1
-13
29.2
-45.4
-5.4
11
3.4
5.9
2.8
1.1
1.5
-0.3
-2.4
-3
2.1
3.5
-0.1
0.8
-0.4
-0.8
-1.2
-0.6
-2.7
-5
-0.9
0.3
-0.9
-0.6
-3.7
0.4
-0.4
-0.2
-0.5

cash-flows.row.account-receivables

-8.09-8.1-16.66.4
-2
24.8
-22.8
-39.9
-2
0
0
0
0
0.1
0.1
-0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

12.4612.5-6.2-6.5
-16.9
14.1
-29.1
-4.8
-5.3
0
0
0
0
1.3
-0.3
-2.1
-2
0
0
0
0
0
0
0
0
-1.6
-0.3
-0.6
5.6
-0.9
1.3
-5.1
-1.2
-0.2
-0.1
-0.1

cash-flows.row.account-payables

0.010-0.63.3
-2.2
-14.1
-1.9
12
3.5
0.8
1.3
-0.4
1
0.5
0
-0.2
-1.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

12.9312.412.8-38.2
8.1
4.5
8.4
27.3
14.8
2.6
4.7
3.2
0.1
-0.3
0
0
0
2.1
3.5
-0.1
0.8
-0.4
-0.8
-1.2
-0.6
-1.1
-4.7
-0.3
-5.3
0
-1.9
1.4
1.6
-0.2
-0.1
-0.4

cash-flows.row.other-non-cash-items

0.413.6-0.30.9
1.4
1.1
0.9
0.8
0.7
0.6
0.6
0.5
0.4
-11.8
0.2
0
0.3
0.5
0.7
0.3
0.3
-2.2
-1
-3.2
-10.9
-0.8
0.2
0.4
1.6
0.6
0.7
0.7
0.2
0.1
-0.1
0.5

cash-flows.row.net-cash-provided-by-operating-activities

-58.79000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-1.54-1.5-1.8-3
-6.8
-7.2
-9.2
-2.6
-3.1
-1.1
-1.4
-1.7
-1
-0.5
-0.1
0
-0.3
-0.5
-0.2
-0.3
-0.2
-0.3
-0.4
-0.3
-0.2
-0.3
-2.7
-2.8
-0.7
-0.9
-0.6
-1.2
-2.4
-0.1
-0.2
-0.7

cash-flows.row.acquisitions-net

-28.1100.20
-215.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.8
0
0.5
0
0
0
0

cash-flows.row.purchases-of-investments

-87.66-87.7-145.7-129.2
-134
-477
-497.1
-121.6
-43.3
-56.1
0
0
0
0
0
0
0
0
-14.7
-8.1
-17.3
-6.7
-12.6
-16.4
-18.9
0
-0.1
0
-0.5
-4.5
-1.4
-6.5
-15.5
-2.3
-7
-1

cash-flows.row.sales-maturities-of-investments

107.19107.2144164.9
349.8
462.4
227.7
131.8
61.3
0
0
0
0
0
0
0.6
1
11.7
7.2
13.5
16.3
8.1
17.5
16.6
3
0
0
0
0.5
5.9
1.2
18.1
3.6
4
7.7
0

cash-flows.row.other-investing-activites

19.54000
215.8
0
0
0.1
0
0.2
0
0
0
0
0
0
0
0
0
0
0
2.1
0.2
3.6
25
-0.1
0
1.8
0
0.1
-0.1
-0.2
-0.1
0
-0.1
0

cash-flows.row.net-cash-used-for-investing-activites

1818-3.332.7
209
-21.8
-278.6
7.7
14.9
-57
-1.4
-1.7
-1
-0.5
-0.1
0.6
0.7
11.2
-7.7
5.1
-1.3
3.3
4.7
3.5
9
-0.4
-2.8
-1
-0.7
1.4
-0.9
10.7
-14.4
1.6
0.4
-1.7

cash-flows.row.debt-repayment

-83.86-24.40-149
0
0
-25
-25
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

29.7629.875.17.1
9.1
162.2
363.1
306.3
0
128.2
58.9
57.8
50.5
22.8
0
8
0.1
37.3
0.1
0.1
12
0.1
0.1
0.1
0.2
0.4
2.3
5.8
7.2
2.5
6
0.3
9.6
1.1
0.7
0.7

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

108.5248.7-0.1297.9
0.1
24.3
19.5
12.5
57.5
9.8
3.2
3.4
3
1.3
0
0
0
0
0
0
0
0
0
0
-3.3
0.2
-2.6
-1.5
-0.1
7.1
4.5
-0.4
9.9
1
1.5
0

cash-flows.row.net-cash-used-provided-by-financing-activities

54.1154.175.1156
9.1
186.4
357.6
293.7
57.5
138
62.1
61.2
53.5
24.1
0.1
8
0.1
37.3
0.1
0.1
12
0.1
0.1
0.1
-3.1
0.6
-0.3
4.3
7.1
9.6
10.5
-0.1
19.5
2.1
2.2
0.7

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

13.3113.3-75.2-14.6
33.2
40.1
-112.7
131.2
-61.8
2.5
0.4
18.8
35.5
15.9
-5.5
-2.4
-23.5
31.2
1.5
-2.3
3
-3.2
-0.3
-2.9
2.8
-0.4
-4.6
3.1
0.3
2.5
1
-1.1
1.2
-0.1
-0.8
-4.8

cash-flows.row.cash-at-end-of-period

104.0928.715.490.5
105.1
71.9
31.8
144.6
13.4
75.2
72.7
72.3
53.5
18
2.1
7.6
10
33.5
2.3
0.8
3.1
0.1
3.3
3.6
6.5
3.7
4.1
8.5
5.4
5.2
2.8
1.7
2.8
1.6
1.8
2.6

cash-flows.row.cash-at-beginning-of-period

90.7815.490.5105.1
71.9
31.8
144.6
13.4
75.2
72.7
72.3
53.5
18
2.1
7.6
10
33.5
2.3
0.8
3.1
0.1
3.3
3.6
6.5
3.7
4.1
8.7
5.4
5.1
2.7
1.8
2.8
1.6
1.7
2.6
7.4

cash-flows.row.operating-cash-flow

-58.79-58.8-146.9-203.4
-184.8
-124.6
-191.8
-170.3
-134.1
-78.5
-60.3
-40.8
-17
-7.7
-5.5
-11
-24.3
-17.3
9.2
-7.5
-7.7
-6.5
-5.1
-6.5
-3.1
-0.6
-1.5
-0.2
-6.1
-8.5
-8.6
-11.7
-3.9
-3.8
-3.4
-3.8

cash-flows.row.capital-expenditure

-1.54-1.5-1.8-3
-6.8
-7.2
-9.2
-2.6
-3.1
-1.1
-1.4
-1.7
-1
-0.5
-0.1
0
-0.3
-0.5
-0.2
-0.3
-0.2
-0.3
-0.4
-0.3
-0.2
-0.3
-2.7
-2.8
-0.7
-0.9
-0.6
-1.2
-2.4
-0.1
-0.2
-0.7

cash-flows.row.free-cash-flow

-60.33-60.3-148.7-206.4
-191.6
-131.7
-201
-172.9
-137.2
-79.6
-61.7
-42.4
-18
-8.2
-5.6
-11
-24.6
-17.8
9
-7.8
-7.9
-6.8
-5.6
-6.8
-3.3
-0.9
-4.2
-3
-6.8
-9.4
-9.2
-12.9
-6.3
-3.9
-3.6
-4.5

Kasumiaruande rida

Heron Therapeutics, Inc. tulud muutusid võrreldes eelmise perioodiga 0.180%. HRTX brutokasum on teatatud 61.94. Ettevõtte tegevuskulud on 172.55, mille muutus võrreldes eelmise aastaga on -24.137%. Kulud amortisatsioonikulud on 2.9, mis on 0.003% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 172.55, mis näitab -24.137% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab 0.367% kasvu võrreldes eelmise aastaga. Tegevustulu on -110.61, mis näitab -0.367% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.178%. Eelmise aasta puhaskasum oli -110.56.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990198919881987

income-statement-row.row.total-revenue

127.04127107.786.3
88.6
146
77.5
30.8
1.3
0
0
0
0
0.6
1.3
1.3
0.4
0.4
0
5.4
5.4
4.8
5.8
4.4
3.4
20.4
20
18.3
18.7
16.1
15.9
19.9
7.3
2.8
2.4
2.8
2.5
1.7

income-statement-row.row.cost-of-revenue

65.1165.154.946
36.2
61.6
27.5
4.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0.4
0.6
6.4
5.7
6
9.4
9.8
9
11.6
3.8
1.1
1.2
0.7
0.6
0.4

income-statement-row.row.gross-profit

61.9461.952.840.3
52.4
84.3
50
26.2
1.2
0
0
0
0
0.6
1.3
1.3
0.4
0.4
0
5.4
5.4
4.8
5.4
3.9
2.8
14
14.3
12.3
9.3
6.3
6.9
8.3
3.5
1.7
1.2
2.1
1.9
1.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

55.9---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

49.01---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

67.64---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0.560.6-7.4-2.9
0.9
5.9
5.1
0
-2.2
-0.7
-1.8
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0.5
1.4
1.2
1.4
1.2
1.1
1.2
1.1
0.8
0.8
0.7
0.9
0.9

income-statement-row.row.operating-expenses

172.55172.6227.5258.2
280.6
295
233.9
220.7
172.2
96.9
74.6
54.5
23.8
11.7
11.2
11.5
23.8
24
18.9
13.9
14.7
11.5
10.2
10.7
7.1
11.3
11.8
12.3
16.3
14.9
15.9
18.7
9.9
5.7
5.9
7.4
7.8
5.4

income-statement-row.row.cost-and-expenses

237.66237.7282.3304.2
316.8
356.7
261.4
225.3
172.2
96.9
74.6
54.5
23.8
11.7
11.2
11.5
23.8
24
18.9
13.9
14.7
11.5
10.6
11.1
7.7
17.7
17.5
18.3
25.7
24.7
24.9
30.3
13.7
6.8
7.1
8.1
8.4
5.8

income-statement-row.row.interest-income

1.233.41.60.4
3.6
7.3
6
1
0
0
0
0
0
0
0
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

33.92.52.4
1.9
1.5
2.7
3.9
2.7
1
0.9
0.8
0.6
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

67.64---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.060.1-7.4-2.9
0.9
5.9
5.1
0
-2.2
-0.7
-1.8
-0.8
-0.6
-0.4
2.7
0
-0.1
2.5
23.4
0
0
0.2
0.1
0.1
0
0
0.2
0.3
-1.1
-0.2
-0.3
0.9
0.8
0.4
1
0.9
1.1
0.5

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0.560.6-7.4-2.9
0.9
5.9
5.1
0
-2.2
-0.7
-1.8
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0.5
1.4
1.2
1.4
1.2
1.1
1.2
1.1
0.8
0.8
0.7
0.9
0.9

income-statement-row.row.total-operating-expenses

0.060.1-7.4-2.9
0.9
5.9
5.1
0
-2.2
-0.7
-1.8
-0.8
-0.6
-0.4
2.7
0
-0.1
2.5
23.4
0
0
0.2
0.1
0.1
0
0
0.2
0.3
-1.1
-0.2
-0.3
0.9
0.8
0.4
1
0.9
1.1
0.5

income-statement-row.row.interest-expense

33.92.52.4
1.9
1.5
2.7
3.9
2.7
1
0.9
0.8
0.6
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

2.92.92.93
2.8
2
1.5
1.5
1.1
0.7
0.6
0.3
0.2
0.2
0.2
0.4
0.4
0.3
-0.2
0.4
0.3
0.5
0.5
0.4
-0.1
0.5
1.4
1.2
1.4
1.2
1.1
1.2
1.1
0.8
0.8
0.7
0.9
0.9

income-statement-row.row.ebitda-caps

-107.72---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-110.61-110.6-174.7-217.8
-228.2
-210.7
-183.9
-194.6
-170.9
-96.9
-74.6
-54.5
-23.8
-11.1
-9.9
-10.2
-23.4
-23.6
-18.9
-8.5
-9.3
-6.6
-4.8
-6.7
-4.3
2.7
2.5
-0.3
-7
-8.6
-9
-10.4
-6.4
-4
-4.7
-5.3
-5.9
-4.1

income-statement-row.row.income-before-tax

-110.56-110.6-182-220.7
-227.3
-204.7
-178.8
-197.5
-173.1
-97.6
-76.4
-55.3
-24.4
-11.4
-7.2
-10.2
-23.1
-19.8
5.5
-8.5
-9.3
-6.5
-4.8
-6.6
-4.3
0
2.7
0
-8.1
-8.8
-9.3
-9.5
-5.8
-4
-3.7
-4.4
-4.8
-3.6

income-statement-row.row.income-tax-expense

-0.290-47.5-3
-2.8
0
7.8
3.9
-1.1
-0.7
-0.6
-0.3
-1.3
0.4
-2.6
-0.1
-0.3
0
0.1
-0.3
-0.1
-2.2
-1
-4.2
-12.9
0.3
0.6
0.7
2.4
0.8
0.8
-0.5
-0.2
0.3
-0.8
-0.8
-0.9
-0.3

income-statement-row.row.net-income

-110.26-110.6-134.5-217.7
-224.4
-204.7
-178.8
-197.5
-173.1
-97.6
-76.4
-55.3
-23.3
-11.8
-7.3
-10
-23.1
-20.2
5.3
-8.2
-9.2
-4.4
-3.8
-2.5
8.6
2.4
1.9
-0.7
-9.4
-9.4
-9.8
-9.9
-5.6
-4.3
-3.9
-4.5
-5
-3.8
Sarnased aktsiad
Sind võib huvitada ka:
MRVI
Maravai LifeSciences Holdings, Inc..
7.7 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0361 USD
NASDAQ
T5O.DE
CytoTools AG.
0.488 EUR
XETRA
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ
SPHRF
Starpharma Holdings Limited.
0.0774 USD
PNK
ARQT
Arcutis Biotherapeutics, Inc..
8.47 USD
NASDAQ

Korduma kippuv küsimus

Mis on Heron Therapeutics, Inc. (HRTX) koguvara?

Heron Therapeutics, Inc. (HRTX) koguvara on 222506000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 65667000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.488.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -0.401.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -0.868.

Mis on ettevõtte kogutulu?

Kogutulu on -0.871.

Mis on Heron Therapeutics, Inc. (HRTX) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -110559000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 179628000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 172554000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 28677000.000.